Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.64 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.64 |
| ▸ | ACHE | P22303 | 12/20 | 0.64 |
| ▸ | BACE1 | P56817 | 12/20 | 0.64 |
| ▸ | BCHE | P06276 | 10/20 | 0.64 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.60 |
| ▸ | CCR5 | P51681 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20492779 | 0.86 | CARM1 (0.68) | CARM1PRMT6ACHEBACE1BCHE | |
| SCHEMBL6704364 | 0.84 | KCNA3 (0.61) | BACE1KCNA3CCR5CYP2D6 | |
| SCHEMBL5272937 | 0.82 | ACHE (0.71) | CARM1PRMT6ACHEBACE1BCHE | |
| SCHEMBL6705454 | 0.82 | KCNA3 (0.67) | KCNA3CCR5CYP2D6 | |
| SCHEMBL6700399 | 0.82 | KCNA3 (0.58) | CARM1PRMT6BACE1KCNA3CCR5 | |
| SCHEMBL6702854 | 0.82 | KCNA3 (0.62) | BACE1KCNA3CCR5CYP2D6 | |
| SCHEMBL4499743 | 0.81 | CARM1 (0.74) | CARM1PRMT6ACHEBACE1BCHE | |
| SCHEMBL3639939 | 0.81 | KCNA3 (0.65) | KCNA3CCR5CYP2D6 | |
| SCHEMBL6701415 | 0.81 | KCNA3 (0.57) | BACE1KCNA3CCR5CYP2D6 | |
| Hydrochloric Acid SCHEMBL6698846 | 0.79 | KCNA3 (0.63) | KCNA3CCR5CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166590-A1 | Microsomal triglyceride transfer protein | WETTERAU JOHN R (US) | 2003-09-04 | — | — | US | disclosed |
| US-6492365-B1 | Microsomal triglyceride transfer protein | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-5789197-A | GENETIC ENGINEERING | E. R. SQUIBB & SONS, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5595872-A | DNA SEQUENCES, CELLS AND EXPRESSION VECTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166590-A1 | Microsomal triglyceride transfer protein | MTTP, CETP, HDLBP | CARM1 3364/4885PRMT6 2966/4885ACHE 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.